Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corticotrophin-releasing hormone (CRH), also known as corticotropin-releasing factor, is a peptide neurohormone produced primarily by the paraventricular nucleus of the hypothalamus. It is the central driver of the hypothalamic–pituitary–adrenal (HPA) axis and plays a key role in coordinating the body's response to stress. CRH stimulates the anterior pituitary gland to secrete adrenocorticotropic hormone (ACTH), which then prompts cortisol release from the adrenal glands[3][1]. Beyond its endocrine effects, CRH acts within various brain regions to modulate appetite, anxiety, memory, and attention. It is also produced in peripheral tissues such as white blood cells and placenta during pregnancy[3]. Synthetic forms like corticorelin are used diagnostically for evaluating ACTH-dependent disorders such as Cushing syndrome and adrenal insufficiency[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corticotrophin-releasing hormone.